Hidradenitis suppurativa
Authors:
M. Arenbergerová; T. Frey; S. Gkalpakiotis; P. Arenberger
Authors‘ workplace:
Dermatovenerologická klinika 3. LF UK a FNKV, Praha, přednosta prof. MUDr. Petr Arenberger, DrSc., MBA
Published in:
Čes-slov Derm, 86, 2011, No. 1, p. 5-11
Category:
Reviews (Continuing Medical Education)
Overview
Hidradenitis suppurativa is a chronic disease characterized by recurrent inflammatory nodules, sinus tracts with suppuration, abscesses and scarring in the skin folds containing terminal hair and apocrine glands. Hidradenitis suppurativa usually manifests after puberty, most often in the third decade; and persists into old age. The prevalence of the disease is approximately 1%. Axillary and inguinal involvement is more common in females, perianal and gluteal areas are predominantly affected in males. The exact etiopathology is still unknown. The primary event is hyperkeratosis leading to follicular occlusion with distension and destruction of infundibulum that provokes large inflammatory reaction in the adjacent tissue. Smoking and obesity may be potential triggering factors. Squamous cell carcinoma and arthropathy belong to the main complications of hidradenitis suppurativa. Treatment depends on the stage of the disease. Topical therapy with antibiotics, antiseptics or long-term systemic antibiotic therapy is suitable for initial and mild forms. In advanced stages, systemic retinoids, antiandrogens, steroids or cyclosporin A are used and anti-TNF drugs have shown promising effect in the severe cases, recently. Total wide excision of the affected area remains the only curative procedure.
Key words:
hidradenitis suppurativa – acne inversa – therapy
Sources
1. ALTMANN, S., FANSA, H., SCHNEIDER, W. Die chirurgische Behandlung der axillären Hidradenitis suppurativa. Chirurg, 2001, 72, p. 1413–1416.
2. BARTH, J. H., LAYTON, A. M., CUNLIFFE, W. J. Endocrine factors in pre- and postmenopausal woman with hidradenitis suppurativa. Br. J. Dermatol., 1996, 134, p. 1057–1059.
3. BREITKOPF, C., BOCKHORST, J., LIPPOLD, A. et al. Pyodermia fistulans sinifica (Akne inversa) und Rauchgewohnheiten. Z. Hautkr., 1995, 70, p. 332–334.
4. BROOK, I., FRAZIER, E. H. Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. J. Med. Microbiol., 1999, 48, p. 103–105.
5. CURTIS, A. C. Cushing´s syndrome and hidradenitis suppurativa. Arch. Dermatol. Syphilol., 1950, 62, p. 329–330.
6. DVORAK, V. C., ROOT, R. K., MACGREGOR, R. R. Host-defense mechanisms in hidradenitis suppurativa. Arch. Dermatol., 1977, 113, p. 450–451.
7. FARELL, A. M., RANDALL, V. A., VAFAEE, T., DAWBER, R. P. R. Finasteride as a therapy for hidradenitis suppurativa. Br. J. Dermatol., 1999, 141, p. 1138–1139.
8. FITZSIMMONS, J. S., GUILBERT, P. R. A family study of hidradenitis suppurativa. J. Med. Genet., 1985, 22, p. 367–373.
9. FROHLICH, D., BAASKE, D., GLATZEL, M. Radiotherapy of hidradenitis suppurativa-still valid today? Strahlender Onkol., 2000, 176, p. 286–289.
10. GIMARELLOS-BOURBOLIS, E. J., PELEKANOU, E., ANTONOPOULOU, A. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br. J. Dermatol., 2008, 158, p. 567–572.
11. GUPTA, A. K. Lithium therapy associated with hidradenitis suppurativa. J. Am. Acad. Dermatol., 1995, 32, p. 382–386.
12. HARRISON, B. J., MUDGE, M., HUGHES, L. E. Recurrence after surgical treatment of hidradenitis suppurativa. Br. Med. J., 1987, 294, p. 487–489.
13. Hidradenitis suppurativa foundation 7895 via Belfiore, San Diego, Kalifornia 92129, Dostupné na www: www.hs.foundation.org.
14. HIGHET, A. S., WARREN, R. E., STAUGHTON, R. C., ROBERTS, S. O. Streptococcus milleri causing treatable infection in perineal hidradenitis suppurativa. Br. J. Dermatol., 1980, 103, p. 375–381.
15. HOFER, T., ITIN, P. H. Acne inversa. Eine Dapson-sensitive Dermatose. Hautarzt, 2001, 52, p. 989–992.
16. HURLEY, H. J. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: Roenigk, R. K. eds. Dermatologic surgery. Marcel Dekker: New York, 1989, p. 729–739.
17. CHOW, E. T., MORTIMER, P. S. Succesfull treatment of hidradenitis suppurativa and retroauricular acne with etretinate. Br. J. Dermatol., 1992, 126, p. 415.
18. JANSEN, T., PLEWIG, G. Acne inversa. Int. J. Dermatol., 1998, 37, p. 96–100.
19. JEMEC, G. B., GNIADECKA, M. Sebum excretion in hidradenitis suppurativa. Dermatology. 1997, 194, p. 325–328.
20. JEMEC, G. B. E., HEIDENHEIM, M., NIELSEN, N. H. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J. Am. Acad. Dermatol., 1996, 35, p. 191–194.
21. JEMEC, G. B. E., WNDELBOE, B. Topical clindamycin versus systemic tetracykline in the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol., 1998, 39, p. 971–974.
22. JOSEPH, M. A., JAYASEELAN, E., GANAPATHI, B., STEHEN, J. Hidradenitis suppurativa treated with finasteride. J. Dermatolog. Treat., 2005, 16, p. 75–78.
23. KRAFT, J. N., SEARLES, G. E. Hidradenitis suppurativa in 64 female patiens retrospective study comparing oral antibiotics and antiandrogen therapy. J. Cutan. Med. Surg., 2007, 11, p. 125–131.
24. KÖNIG, A., LEHMANN, C., ROMPEL, R., HAPPLE, R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology, 1999, 198, p. 261–264.
25. LAPINS, J., JARSTRAND, C., EMTESTAM, L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br. J. Dermatol., 1999, 140, p. 90–95.
26. LAPINS., J., SARTORIUS, K., EMTESTAM, L. Scanner--assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J. Am. Acad. Dermtol., 2002, 47, p. 280–285.
27. O’LOUGHLIN, S., WOODS, R., KIRKE, PN. et al. Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic and immunologic features and HLA frequencies in 27 patients. Arch. Dermatol., 1988, 124, p. 1043–1046.
28. MAHE, E., MORELSON, E., LECHATON, S. et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation, 2005, 79, p. 476–482.
29. MENDONCA, C. O., GRIFFITH, C. E. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br. J. Dermatol., 2006, 154, p. 977–978.
30. MENDONCA, H., REBELO, C., FERNARDES, A. et al. Squamous cell carcinoma arising in chronic hidradenitis suppurativa. J. Dermatol. Surg. Oncol., 1991, 17, p. 830–832.
31. MORGAN, W. P., LEICESTER, G. The role of depilation and deodorants in hidradenitis suppurativa. Arch. Dermatol., 1982, 118, p. 101–102.
32. MORTIMER, P. S., DAWBER, R. P., GALES, M. A., MOORE, R. A. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br. J. Dermatol., 1986, 115, p. 263–268.
33. NALDI, L. Epidemiology. In: JEMEC, G., REVUZ, J., LEDEN, J. eds. Hidradenittis suppurativa, Vol. 1, Springer, 2006, p. 58–64.
34. NORRIS, J. F. B., CUNLIFFE, W. J. Hidradenitis suppurativa and response to oral steroids. Br. J. Dermatol., 1987, 117, Suppl 32, p. 96.
35. PALMER, R. A., KEEFE, M. Early-onset hidradenitis suppurativa. Clin. Exp. Dermatol., 2001, 26, p. 501–503.
36. PILLSBURY, D. M., SHELLEY, W. B. KLIGMAN, A. M. Dermatology. 1st edn. Saunders, Philadelphia, 1956, p. 482–484.
37. PLEWIG, G., STEGER, M. Acne inversa (alias acne triad, acne tetrade or hidradenitis suppurativa). In: MARKS, R., PLEWIG, G. editors. Acne and Related Disorders. Martin Dunitz: London, 1989, p. 345–357.
38. O’REILLY, D. J., PLEAT, J. M., RICHARDS, A. M. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast. Reconstr. Surg., 2005, 116, p. 1575–1576.
39. ROSNER, I. A., BURG, C. G., WINIEVSKI, J. J. The clinical spectrum of the arthropathy associated with hidradenitis suppurativa and acne conglobata. J. Rheumatol., 1993, 20, p. 684–687.
40. SEKSIK, P., CONTOU, J. F., COSNES, A., COSNES, J. Hidradenitis suppurativa and Crohn’s disease. In: JEMEC, G., REVUZ, J., LEDEN, J. eds. Hidradenittis suppurativa Vol. 1, Springer, 2006, p. 50–57.
41. SORIA, A., CANOUI-POITRINE, F., WOLKENSTEIN, P. et al. Abscence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’outcome assessment. Dermatology, 2009, 218, p. 134–135.
42. SPILLER, J. F., KNOX, J. Fox-Fordyce disease with hidradenitis suppurativa. J. Invest. Dermatol., 1958, 31, p. 127–135.
43. STRAUSS, R. M., POLLOCK, B., STABLES, G. I., GOULDEN, V., CUNLIFFE, W. J. Photodynamic therpay using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br. J. Dermatol., 2005, 152, p. 803–804.
44. SULLIVAN, T. P., WELSH, E., KERDEL, F. A. Infliximab for hidradenitis suppurativa. Br. J. Dermatol., 2003, 149, p. 1046–1049.
45. TSIANOS, E. V., DALEKOS, G. N., TZERMIAS, C. Hidradenitis suppurativa in Crohn´s disease. A further support to this association. J. Clin. Gastroenterol., 1995, 20, p. 151–153.
46. VERNEUIL, A. Études sur les tumeurs de la peau et quelques maladies des glandes sudoripares. Arch. Gén. Méd., 1854, p. 447–468.
47. von der WERTH, J. M., JEMEC, G. B. Morbidity in patiens with hidradenitis suppurativa. Br. J. Dermatol., 2001, 144, p. 809–813.
48. von der WERTH, J. M., WILLIAMS, H. C. The natural history of hidradenitis suppurativa. J. Eur. Acad. Venereol., 2000, 14, p. 389–392.
49. von der WERTH, J. M., WILLIAMS, H. C., REABURN, J. A. The clinical genetics of hidradenitis suppurativa revisited. Br. J. Dermatol., 2000, 142, p. 947–953.
50. WOLKENSTEIN, P., LOUNDOU, A., BARRAU, K. et al. Quality of life impairment in hidradenitis suppurativa. A study of 61 cases. J. Am. Acad. Dermatol., 2007, 56, p. 621–623.
51. YAMAUCHI, P. S., MAU, N. Hidradenitis suppurativa managed with adalimumab. J. Drugs Dermatolog., 2009, 8, p. 181–183.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2011 Issue 1
Most read in this issue
- Successful Treatment of Severe Hidradenitis Suppurativa with Adalimumab
- Hidradenitis suppurativa
- Clinical Pathological Aspects of Pendulating Soft Fibroma
- Autoimmune Hepatitis during by Infliximab Treatment of Psoriasis: Case Report